Plasma Derived Medicine Market Size to Reach USD 37.4 Billion by 2034

Plasma Derived Medicine Market Companies, Trends and Growth Analysis

The global plasma derived medicine market size was estimated at US$ 15.96 billion in 2023 and is projected to grow to US$ 37.4 billion by 2034, rising at a compound annual growth rate (CAGR) of 8.05% from 2024 to 2034. Plasma-derived medicines are in high demand due to their use in various plasma protein dysfunctions and deficiencies.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The plasma derived medicine market encompasses the production of plasma-derived products or medicines that are further used during the treatment of health issues that require specific plasma-based products. Plasma-derived medicines include coagulation factors, albumin, and immunoglobin. The demand for these products is increasing because they are used as therapeutics in many chronic and acute life-threatening diseases.

Plasma Derived Medicine Market Trends

• In September 2024, Viromed Medical AG will purchase all of ActivCell Group's shares. To agree, they will "immediately" start more talks. For the first time, plasma medicine may be easily employed in everyday practice thanks to the Swiss ActivCell Group's CellPen device line, which effectively incorporates cold plasma technology into tiny cordless devices, or "pens."
• In December 2023, the biopharmaceutical business PlasmaGen Biosciences secured approximately $27 million, or Rs 225 crore, in equity capital. The money raised will help the Bengaluru-based business expand its line of plasma goods.
• In May 2023, New York Blood Center, Inc. (NYBC) invested $50 million in NYBC Ventures' first fund, which was launched to spur innovation in cellular treatments, enabling technologies, and blood-related sectors.

Plasma Derived Medicine Market has Numerous Opportunities

In the near future, PDMPS is expected to worsen because of the aging population and better healthcare, which leads to better diagnosis and treatment. Discovering novel therapeutic indications and diseases that PDMPs can cure will be essential. There doesn't seem to be a replacement for IVIG. Thus, its therapeutic use will be expanded by potential new indications in neurological conditions such as neuropathic pain, chronic fatigue syndrome, post-polio syndrome, and others. Researchers are also looking at other uses for albumin, such as sepsis, cirrhosis, stroke, Alzheimer's disease, and malaria.

Plasma Derived Medicine Market Challenge: High Cost

Medicines made from plasma are the result of costly methods that use human plasma, a complicated raw material. These items are expensive due to their numerous safety precautions, pricey raw materials, and sophisticated technology.

Regional Insights

North America dominated the plasma derived medicine market in 2023.

North America dominated the market for many reasons. First of all, the region has advanced healthcare infrastructure, which ensures that the people in the region get proper and high-quality care. Secondly, the key market players in the region continuously conduct R&D, innovate, and collaborate with other organizations to develop better products. Apart from this, various government and non-government organizations invest time, resources, and money to support clinical trials, research, awareness programs, and healthcare programs to improve the healthcare system. The citizens in the region are also aware of their healthcare rights and facilities, which ensures that they utilize the resources properly. A lot of people make sure to take proper health services due to health insurance. Moreover, a lot of campaigns conducted by the organization about blood donation and awareness about the importance of blood donation encourage people to participate in blood donation programs. The blood plasma derived medicine market is growing in the region mainly due to contributions from the U.S. and Canada.

For instance,

• The U.S. FDA Blood Establishment Registration database indicates that there are 90 hospital-based blood centers and 53 community blood centers. The American Red Cross collects around 40% of the country's blood supply, while independent community blood centers gather about 60%. 204.9 million eligible donors, or 62% of the whole U.S. population, are eligible to donate.
• In November 2023, the "Give 3 in 2023 Campaign," started by Canadian Blood Services, invites individuals to help patients by donating platelets, plasma, or blood.

Asia Pacific is expected to grow at the fastest rate during the forecast period.

The region's plasma derived medicine market is growing due to growing awareness of blood donations. Government and non-government organizations are conducting many campaigns and awareness programs to increase blood donation. Apart from this, the number of blood banks is also increasing in the region, which ensures that people can get blood products like plasma-derived medicines on time. Along with this, many key market players are actively expanding the production of plasma-derived products in the region due to the growing prevalence of diseases. China, India, Japan, and South Korea are the major countries contributing to the growth of the plasma derived medicine market.

For instance,

• Data from the Chinese National Health Commission shows that voluntary blood donations reached a record high in China in 2023, totaling 16.99 million donations, up 5.9 percent from 2022.
• There are 402 million people in India that can donate. In 2022, the expected number of blood donations in the nation was 33.8 per thousand.

Segmental Insights

By product, the immunoglobin segment held the largest share of the plasma derived medicine market in 2023. Intravenous (IVIG) and subcutaneous (ScIG) immunoglobulin therapy is constantly growing and is currently recommended as a treatment for a number of immunodeficiencies and immune-mediated illnesses. Both newly recognized indications and a number of rising off-label indications contribute to the growing global use.

The coagulation factors segment is anticipated to grow significantly during the forecast period. Coagulation factors are mainly used in bleeding disorders like hemophilia, where patients lack enough clotting factors to prevent bleeding.

By application, the bleeding disorders segment held the largest share of the plasma derived medicine market in 2023. High coagulation factor concentrate expenses are linked to treating individuals with hemophilia A. Boys are more likely than girls to be born with hemophilia A and B, which are estimated to affect 1 in 5000 and 1 in 30,000 babies worldwide, respectively. As a result, it is reasonable to assume that there are about 1.1 million hemophiliacs worldwide, of whom approximately 400,000 are likely to experience severe hemophilia. Even in wealthy nations like the United States, Germany, Japan, and others, the annual cost of blood clotting factors for treating a single patient with hemophilia B can run up to $450,000, and the total cost of therapy can potentially approach $20 million or more.

By distribution channel, the hospital pharmacies segment led the plasma derived medicine market in 2023. Patients with bleeding disorders or other health issues that require plasma medicine need proper medical attention, so they are admitted to hospitals. Pharmacies associated with hospitals become major suppliers of medicines. Therapeutics are easily accessible and given under the guidance of professionals.

The online pharmacies segment is estimated to grow rapidly in the plasma-derived medicine market during the forecast period. Online pharmacies are gaining popularity due to their ease of accessibility. People who need plasma-derived medicines can easily get their medicines delivered to their doorsteps.

Recent Developments

• In June 2024, CSL Behring, a division of the world's leading biotechnology company, is the manufacturer of Haemocomplettan® P (Human Fibrinogen Concentrate), which was recently introduced by Bengaluru-based Plasmagen Biosciences, which specializes solely in Plasma Protein and Specialty Care Therapy.
• In February 2024, according to Jörg Schüttrumpf, chief scientific innovations officer, Grifols intends to publish Phase III findings of their long-term albumin therapy in 2024. This medication lengthens the life period for patients with decompensated cirrhosis and ascites.

Top Companies in the Plasma Derived Medicine Market

• Biotest AG
• Kameda Pharmaceuticals
• ADMA Biologics
• Shanghai RAAS
• Kedrion
• China Biologic Products Holdings
• Bio Products Laboratory
• CSL Limited
• Octapharma AG
• LFB
• Takeda
• Fusion Healthcare
• SK Plasma
• Grifols, S.A

Segments Covered in the Report

By Product

• Immunoglobin
• Coagulation Factors
• Albumin
• Others

By Application

• Bleeding Disorders
• Alpha-1 Antitrypsin Deficiency (AATD)
• Pelvic Inflammatory Disease (PID)
• Hereditary Angioedema (HAE)
• Chronic Inflammatory Demyelinating Polyneuropathy
• Guillian=Barre Syndrome
• Multifocal Motor Neuropathy
• Liver Disease
• Primary Immune Thrombocytopenia
• Infections
• Other Orphan Diseases

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait